{"protocolSection":{"identificationModule":{"nctId":"NCT02072226","orgStudyIdInfo":{"id":"ML29093"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke","officialTitle":"A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)","acronym":"PRISMS"},"statusModule":{"statusVerifiedDate":"2018-06","overallStatus":"TERMINATED","whyStopped":"The study was terminated due to slow enrollment.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-05-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-22","type":"ACTUAL"},"completionDateStruct":{"date":"2017-03-22","type":"ACTUAL"},"studyFirstSubmitDate":"2014-02-24","studyFirstSubmitQcDate":"2014-02-24","studyFirstPostDateStruct":{"date":"2014-02-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-07","resultsFirstSubmitQcDate":"2018-06-04","resultsFirstPostDateStruct":{"date":"2018-07-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-06-04","lastUpdatePostDateStruct":{"date":"2018-07-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes that do not appear to be clearly disabling. Participants will be randomized in a 1:1 ratio to receive within 3 hours of last known well time either 1) one dose of IV alteplase and one dose of oral aspirin placebo or 2) one dose of IV alteplase placebo and one dose of oral aspirin 325 milligrams (mg)."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":313,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alteplase Placebo + Aspirin","type":"ACTIVE_COMPARATOR","description":"Participants will receive single dose of IV alteplase placebo and aspirin orally.","interventionNames":["Drug: Alteplase Placebo","Drug: Aspirin"]},{"label":"Alteplase + Aspirin Placebo","type":"EXPERIMENTAL","description":"Participants will receive single dose of IV alteplase and aspirin placebo orally.","interventionNames":["Drug: Alteplase","Drug: Aspirin Placebo"]}],"interventions":[{"type":"DRUG","name":"Alteplase","description":"Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).","armGroupLabels":["Alteplase + Aspirin Placebo"],"otherNames":["Activase; RO5532960"]},{"type":"DRUG","name":"Alteplase Placebo","description":"Single dose of alteplase placebo will be administered as IV injection.","armGroupLabels":["Alteplase Placebo + Aspirin"]},{"type":"DRUG","name":"Aspirin","description":"Single dose of aspirin will be administered at 325 mg orally.","armGroupLabels":["Alteplase Placebo + Aspirin"]},{"type":"DRUG","name":"Aspirin Placebo","description":"Single dose of aspirin placebo will be administered orally.","armGroupLabels":["Alteplase + Aspirin Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90","description":"mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS.","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"Distribution of Participants Across the Ordinal mRS","description":"mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS.","timeFrame":"Day 90"},{"measure":"Percentage of Participants With Global Favorable Recovery on mRS, NIHSS, BI, and GOS","description":"Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index \\[BI\\] greater than or equal to 95, and Glasgow Outcome Scale \\[GOS\\] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales.","timeFrame":"Day 90"},{"measure":"Percentage of Participants With Symptomatic Intracranial Hemorrhage (ICH )","description":"ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.","timeFrame":"Within 36 hours after study drug administration on Day 1"},{"measure":"Percentage of Participants With Any ICH","description":"To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.","timeFrame":"Within 36 hours after study drug administration on Day 1"},{"measure":"Overall Mortality","description":"Reported here is the percentage of participants who died due to any cause during the study.","timeFrame":"From baseline to Day 90"},{"measure":"Percentage of Participants Who Died Due to Stroke and Neurological Disorders","description":"Reported here is the percentage of participants who died due to stroke and neurological disorders.","timeFrame":"From baseline to Day 90"},{"measure":"Percentage of Participants With Adverse Events","description":"An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","timeFrame":"From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90."},{"measure":"Percentage of Participants With Serious Adverse Events","description":"A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.","timeFrame":"From baseline to Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Mild ischemic stroke defined as the most recent pre-treatment NIHSS score of less than or equal to(\\</=) 5 and determined as not clearly disabling by the investigator\n* Study treatment initiated within 3 hours of last time participant seen normal\n\nExclusion Criteria:\n\n* Computed tomography (CT) or magnetic resonance imaging (MRI) findings of one of the following:\n\n  1. CT with clear large hypodensity that is greater than (\\>) one-third middle cerebral artery (MCA) territory (or \\>100 cubic centimeter \\[cc\\] if not in MCA territory)\n  2. MRI with clear large hyperintensity on concurrent diffusion-weighted (DW) and fluid-attenuated inversion recovery (FLAIR) that is greater than one-third MCA territory (or greater than 100 cc if not in MCA territory),\n  3. Imaging lesion consistent with acute hemorrhage, or\n  4. Evidence of intraparenchymal tumor\n* Disability prior to the presenting stroke\n* Standard contraindications to IV alteplase within 3 hours of symptom onset, including:\n\n  1. Head trauma, myocardial infarction, or previous stroke within the previous 3 months\n  2. Gastrointestinal or urinary tract hemorrhage within the previous 21 days\n  3. Major surgery within the previous 14 days\n  4. Arterial puncture at non-compressible site within the previous 7 days\n  5. Any history of ICH with the exception of those less than (\\<) 5 chronic microbleeds on MRI\n  6. Elevated blood pressure defined by systolic blood pressure \\>185 millimeters of mercury (mm Hg) or diastolic blood pressure \\>110 mm Hg, or treatments requiring aggressive measures to achieve acceptable levels\n  7. Treatment with unfractioned heparin within past 48 hours and activated partial thromboplastin time outside normal range\n  8. Blood glucose \\<50 milligrams per deciliter (mg/dL)\n  9. International normalized ratio \\>1.7\n  10. Platelet count \\<100,000 per cubic millimeter (/mm\\^3)\n  11. Treatment with a direct thrombin inhibitor (dabigatran) or a factor Xa inhibitor (apixaban, rivaroxaban, edoxaban) within the last 48 hours\n* Allergic reaction to study drug, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)\n* Females of childbearing age who are known to be pregnant and/or lactating\n* Inability to swallow, which would prevent oral intake of aspirin or aspirin placebo tablet\n* Other serious, advanced, or terminal illness that would confound the clinical outcome at 90 days\n* Current or recent (within 3 months) participation in another investigational drug treatment protocol\n* Anticipated inability to obtain 3-month follow-up assessments\n* Previous enrollment in PRISMS\n* Any other condition deemed by the investigator that would pose hazard to the participant with alteplase treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Genentech, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35294-3300","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Banner Good Samaritan Medical Center","city":"Phoenix","state":"Arizona","zip":"85006","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"University of Arizona","city":"Tucson","state":"Arizona","zip":"85724-5030","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"St. Jude Medical Center","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"University of California San Diego","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Cedars Sinai Medical Center","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Hoag Memorial Hospital","city":"Newport Beach","state":"California","zip":"92658","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"University of California Los Angeles","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01945,"lon":-118.49119}},{"facility":"Colorado Neurological Institute","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"Poudre Valley Hospital","city":"Fort Collins","state":"Colorado","zip":"80524","country":"United States","geoPoint":{"lat":40.58526,"lon":-105.08442}},{"facility":"Medical Center of The Rockies","city":"Loveland","state":"Colorado","zip":"80538","country":"United States","geoPoint":{"lat":40.39776,"lon":-105.07498}},{"facility":"Associated Neurologists PC","city":"Danbury","state":"Connecticut","zip":"06810","country":"United States","geoPoint":{"lat":41.39482,"lon":-73.45401}},{"facility":"Associated Neurologists of Southern CT PC","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Hartford Hospital","city":"Hartford","state":"Connecticut","zip":"06102","country":"United States","geoPoint":{"lat":41.76371,"lon":-72.68509}},{"facility":"Christiana Care Health Services; Sponsor Programs Ammon Education Center","city":"Newark","state":"Delaware","zip":"19718-0002","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Nova Clinical Research, LLC","city":"Bradenton","state":"Florida","zip":"34209","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"Neurologic Consultants, P.A.","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"University of Miami Miller School of Medicine; Clinical Reseach Building","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Rush University Medical Center","city":"Chicago","state":"Illinois","zip":"60612-3244","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Alexian Brothers Neuroscience Institute","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"Parkview Research Center","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"University of Kansas Medical Center","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"St. Elizabeth Edgewood; Cancer Care Center\" for Account St. Elizabeth Edgewood","city":"Edgewood","state":"Kentucky","zip":"41017","country":"United States","geoPoint":{"lat":39.01867,"lon":-84.58189}},{"facility":"University of Louisville","city":"Elizabethtown","state":"Kentucky","zip":"42791","country":"United States","geoPoint":{"lat":37.69395,"lon":-85.85913}},{"facility":"St. Elizabeth Florence","city":"Florence","state":"Kentucky","zip":"41042","country":"United States","geoPoint":{"lat":38.99895,"lon":-84.62661}},{"facility":"St. Elizabeth Fort Thomas","city":"Fort Thomas","state":"Kentucky","zip":"41075","country":"United States","geoPoint":{"lat":39.07506,"lon":-84.44716}},{"facility":"University of Kentucky","city":"Lexington","state":"Kentucky","zip":"40536","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Sinai Hospital of Baltimore","city":"Baltimore","state":"Maryland","zip":"21215","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Northwest Hospital Center","city":"Randallstown","state":"Maryland","zip":"21133","country":"United States","geoPoint":{"lat":39.36733,"lon":-76.79525}},{"facility":"Detroit Receiving Hospital","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Sparrow Health System","city":"Lansing","state":"Michigan","zip":"48909","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"St Joesph Mercy Hospital Oakland","city":"Pontiac","state":"Michigan","zip":"48341","country":"United States","geoPoint":{"lat":42.63892,"lon":-83.29105}},{"facility":"Beaumont Hospital","city":"Royal Oak","state":"Michigan","zip":"48073","country":"United States","geoPoint":{"lat":42.48948,"lon":-83.14465}},{"facility":"The Minneapolis Clinic of Neurology","city":"Golden Valley","state":"Minnesota","zip":"55422","country":"United States","geoPoint":{"lat":45.00969,"lon":-93.34912}},{"facility":"University of Mississippi Medical Center","city":"Jackson","state":"Mississippi","zip":"39216","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"University of Missouri Health Care","city":"Columbia","state":"Missouri","zip":"65212","country":"United States","geoPoint":{"lat":38.95171,"lon":-92.33407}},{"facility":"Washington University","city":"Saint Louis","state":"Missouri","zip":"63128","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Renown Health; Renown Institute for Neurosciences","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Hackensack University Medical Center","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Overlook Hospital","city":"Summit","state":"New Jersey","zip":"07902","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Shore Neurology","city":"Toms River","state":"New Jersey","zip":"08755","country":"United States","geoPoint":{"lat":39.95373,"lon":-74.19792}},{"facility":"SUNY Downstate Medical Center.","city":"Brooklyn","state":"New York","zip":"11203","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Lutheran Medical Center","city":"Brooklyn","state":"New York","zip":"11220","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Buffalo General Medical Center","city":"Buffalo","state":"New York","zip":"14203","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Ichan School of Medicine at Mount Sinai","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University of North Carolina At Chapel Hill","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Guilford Neurologic Associates","city":"Greensboro","state":"North Carolina","zip":"27401","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Wake Forest Baptist Medical Center","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Akron General Medical Center","city":"Akron","state":"Ohio","zip":"44307","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"facility":"University of Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45203-0542","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"West Hospital","city":"Cincinnati","state":"Ohio","zip":"45211","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"The Christ Hospital","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Jewish Hospital","city":"Cincinnati","state":"Ohio","zip":"45236","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Anderson Hospital","city":"Cincinnati","state":"Ohio","zip":"45255","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Case Western Reserve University","city":"Cleveland","state":"Ohio","zip":"44109","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Cleveland Clinic","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Riverside Methodist Hospital","city":"Columbus","state":"Ohio","zip":"43214","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Wright State University","city":"Dayton","state":"Ohio","zip":"45409","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Fairfield Hospital","city":"Fairfield","state":"Ohio","zip":"45014","country":"United States","geoPoint":{"lat":39.34589,"lon":-84.5605}},{"facility":"University of Toledo Medical Center","city":"Toledo","state":"Ohio","zip":"43614","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"Providence Portland Medical Center","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Providence Saint Vincent's Medical Center","city":"Portland","state":"Oregon","zip":"97225","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Lehigh Valley Hospital","city":"Allentown","state":"Pennsylvania","zip":"18105","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"Penn State Hershey Medical Center","city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}},{"facility":"Thomas Jefferson University","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Temple University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Albert Einstein Healthcare Network","city":"Philadelphia","state":"Pennsylvania","zip":"19141","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"University of Pittsburgh Cancer Institute","city":"Pittsburgh","state":"Pennsylvania","zip":"15219","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"York Hospital","city":"York","state":"Pennsylvania","zip":"17403","country":"United States","geoPoint":{"lat":39.9626,"lon":-76.72774}},{"facility":"Medical University of South Carolina; MSC 300","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77657,"lon":-79.93092}},{"facility":"University of South Carolina School of Medicine","city":"Columbia","state":"South Carolina","zip":"29203-7606","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"The Neurology And Pain Clinic","city":"Orangeburg","state":"South Carolina","zip":"29118","country":"United States","geoPoint":{"lat":33.49182,"lon":-80.85565}},{"facility":"Chattanooga Center for Neurologic Research","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"University of Tennessee Medical Center","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Valley Baptist Medical Center","city":"Harlingen","state":"Texas","zip":"78550","country":"United States","geoPoint":{"lat":26.19063,"lon":-97.6961}},{"facility":"Methodist Neurological Institute","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University Of Texas Health Science Center Houston","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Texas Tech Univ Health Sci Ctr","city":"Lubbock","state":"Texas","zip":"79430","country":"United States","geoPoint":{"lat":33.57786,"lon":-101.85517}},{"facility":"University Hospital San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"University Of Utah","city":"Salt Lake City","state":"Utah","zip":"84108","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Inova Fairfax Hospital","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Swedish Medical Center","city":"Seattle","state":"Washington","zip":"98122","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"West Virginia University Hospital","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Gunderson Health System","city":"La Crosse","state":"Wisconsin","zip":"54601","country":"United States","geoPoint":{"lat":43.80136,"lon":-91.23958}},{"facility":"University of Wisconsin","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}}]},"referencesModule":{"references":[{"pmid":"29998337","type":"DERIVED","citation":"Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, Chatterjee A, Jauch EC, Levine SR, Romano JG, Saver JL, Vagal A, Purdon B, Devenport J, Pavlov A, Yeatts SD; PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):156-166. doi: 10.1001/jama.2018.8496."},{"pmid":"25638754","type":"DERIVED","citation":"Zhao W, Mu Y, Tayama D, Yeatts SD. Comparison of statistical and operational properties of subject randomization procedures for large multicenter clinical trial treating medical emergencies. Contemp Clin Trials. 2015 Mar;41:211-8. doi: 10.1016/j.cct.2015.01.013. Epub 2015 Jan 29."},{"pmid":"25628404","type":"DERIVED","citation":"Choi JC, Jang MU, Kang K, Park JM, Ko Y, Lee SJ, Cha JK, Kim DH, Park SS, Park TH, Lee KB, Lee J, Kim JT, Cho KH, Yu KH, Oh MS, Lee BC, Cho YJ, Kim DE, Lee JS, Lee J, Gorelick PB, Bae HJ. Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke. J Am Heart Assoc. 2015 Jan 27;4(1):e001306. doi: 10.1161/JAHA.114.000596."}],"seeAlsoLinks":[{"label":"PRISMS website","url":"http://prisms-stroke-study.com/"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 milligram per kilogram (mg/kg) (maximal dose of 90 mg) intravenous (IV) alteplase and aspirin placebo orally."},{"id":"FG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"157"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"141"},{"groupId":"FG001","numSubjects":"147"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Patient Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Patient Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-Treat (ITT) population included all randomized participants.","groups":[{"id":"BG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"BG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"313"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.94","spread":"13.53"},{"groupId":"BG001","value":"61.20","spread":"13.05"},{"groupId":"BG002","value":"61.57","spread":"13.27"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"144"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"169"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"32"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"273"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"62"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"243"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Total National Institutes of Health Stroke Scale (NIHSS)","description":"NIHSS measures stroke symptoms. It has 11 main items which score between 0 and 4. A score of 0 typically indicates normal function, and a higher score indicates more symptoms. The individual scores from each item are summed to calculate total NIHSS score. Total NIHSS score ranges from 0 to 42, with 0 indicating no stroke symptoms, and a higher score indicating more symptoms.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.3","spread":"1.21"},{"groupId":"BG001","value":"2.1","spread":"1.15"},{"groupId":"BG002","value":"2.2","spread":"1.18"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90","description":"mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS.","populationDescription":"Intent-to-Treat (ITT) population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2"},{"groupId":"OG001","value":"81.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"Adjusted Risk Difference","paramValue":"-1.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.44","ciUpperLimit":"7.25"}]},{"type":"SECONDARY","title":"Distribution of Participants Across the Ordinal mRS","description":"mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS.","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}]}],"classes":[{"title":"mRS at Day 90 - 0","categories":[{"measurements":[{"groupId":"OG000","value":"44.9"},{"groupId":"OG001","value":"50.3"}]}]},{"title":"mRS at Day 90 - 1","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"31.2"}]}]},{"title":"mRS at Day 90 - 2","categories":[{"measurements":[{"groupId":"OG000","value":"11.5"},{"groupId":"OG001","value":"11.5"}]}]},{"title":"mRS at Day 90 - 3","categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"3.2"}]}]},{"title":"mRS at Day 90 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"5.1"},{"groupId":"OG001","value":"2.5"}]}]},{"title":"mRS at Day 90 - 5 or 6 (death)","categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"1.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"Odds Ratio (OR)","paramValue":"0.810","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.527","ciUpperLimit":"1.244"}]},{"type":"SECONDARY","title":"Percentage of Participants With Global Favorable Recovery on mRS, NIHSS, BI, and GOS","description":"Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index \\[BI\\] greater than or equal to 95, and Glasgow Outcome Scale \\[GOS\\] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales.","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}]}],"classes":[{"title":"mRS 0 - 1 at Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.2"},{"groupId":"OG001","value":"81.5"}]}]},{"title":"NIHSS 0 - 1 at Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.0"},{"groupId":"OG001","value":"81.7"}]}]},{"title":"BI >= 95 at Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.3"},{"groupId":"OG001","value":"88.7"}]}]},{"title":"GOS = 1 at Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.5"},{"groupId":"OG001","value":"85.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"Odds Ratio (OR)","paramValue":"0.858","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.529","ciUpperLimit":"1.393"}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Intracranial Hemorrhage (ICH )","description":"ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Within 36 hours after study drug administration on Day 1","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"difference in percentages","paramValue":"3.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.75","ciUpperLimit":"7.38"}]},{"type":"SECONDARY","title":"Percentage of Participants With Any ICH","description":"To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Within 36 hours after study drug administration on Day 1","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"title":"Any ICH within 36 hours reported by site","categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"2.6"}]}]},{"title":"Any ICH within 36 hours reported by central reader","categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"3.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Any ICH within 36 hours reported by site","nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"difference in percentages","paramValue":"4.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.34","ciUpperLimit":"10.07"},{"groupIds":["OG000","OG001"],"groupDescription":"Any ICH within 36 hours reported by central reader","nonInferiorityType":"OTHER","nonInferiorityComment":"Confidence Interval","paramType":"difference in percentages","paramValue":"3.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.23","ciUpperLimit":"9.49"}]},{"type":"SECONDARY","title":"Overall Mortality","description":"Reported here is the percentage of participants who died due to any cause during the study.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From baseline to Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died Due to Stroke and Neurological Disorders","description":"Reported here is the percentage of participants who died due to stroke and neurological disorders.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From baseline to Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90.","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3"},{"groupId":"OG001","value":"68.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serious Adverse Events","description":"A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.","populationDescription":"Safety Population included all participants, who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From baseline to Day 90","groups":[{"id":"OG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally."},{"id":"OG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0"},{"groupId":"OG001","value":"13.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious adverse events were collected from baseline through the end of study at Day 90. Non-serious adverse events were collected from baseline through the Day 30 visit.","description":"Safety population included all participants, who received any amount of study drug.","eventGroups":[{"id":"EG000","title":"Alteplase + Aspirin Placebo","description":"Participants received single dose of 0.9 mg/kg (maximal dose of 90 mg) IV alteplase and aspirin placebo orally.","deathsNumAffected":1,"deathsNumAtRisk":154,"seriousNumAffected":40,"seriousNumAtRisk":154,"otherNumAffected":49,"otherNumAtRisk":154},{"id":"EG001","title":"Alteplase Placebo + Aspirin","description":"Participants received single dose of IV alteplase placebo and 325 mg aspirin orally.","deathsNumAffected":0,"deathsNumAtRisk":153,"seriousNumAffected":20,"seriousNumAtRisk":153,"otherNumAffected":53,"otherNumAtRisk":153}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Splenic embolism","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Cardiac aneurysm","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Volvulus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Ophthalmic herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Fracture displacement","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Subarachnoid haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Benign ovarian tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":154},{"groupId":"EG001","numAffected":2,"numAtRisk":153}]},{"term":"Stroke in evolution","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":2,"numAtRisk":153}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":3,"numAtRisk":153}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":2,"numAtRisk":153}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Carotid arteriosclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Toxic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Device loosening","organSystem":"Product Issues","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Renal embolism","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":154},{"groupId":"EG001","numAffected":1,"numAtRisk":153}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":154},{"groupId":"EG001","numAffected":0,"numAtRisk":153}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":154},{"groupId":"EG001","numAffected":13,"numAtRisk":153}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":154},{"groupId":"EG001","numAffected":10,"numAtRisk":153}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":154},{"groupId":"EG001","numAffected":12,"numAtRisk":153}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":154},{"groupId":"EG001","numAffected":9,"numAtRisk":153}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":154},{"groupId":"EG001","numAffected":26,"numAtRisk":153}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":154},{"groupId":"EG001","numAffected":10,"numAtRisk":153}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The study was terminated early due to low enrollment, leading to smaller number of participants analyzed."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"1-800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-05-17","uploadDate":"2018-03-06T04:50","filename":"SAP_000.pdf","size":1674179},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2015-01-08","uploadDate":"2018-03-07T06:11","filename":"Prot_001.pdf","size":20124696}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}